According to the statistics of the World Health Organization, there are more than 300 million people infected with chronic hepatitis B virus in the world, including about 200 million people in China. There are about 30 million hepatitis B patients in China, of which about 25% eventually died of some secondary diseases of hepatitis B, including chronic active hepatitis B, liver cirrhosis, liver cancer and so on. Therefore, it is of great significance to treat hepatitis B patients and chronic hepatitis B carriers.
At present, there are many kinds of drugs for treating hepatitis B in the world, but there is a lack of specific drugs for radical treatment of hepatitis B. "Targeted preparation of human monoclonal antibodies against hepatitis B virus" is a frontier project with international advanced level, and human monoclonal antibodies for treating hepatitis B are a key project in the world. In this project, firstly, an engineering cell line that can produce a large number of human monoclonal antibodies against hepatitis B virus was established, and secondly, the cross-linking technology between antibodies and interferon was established. After patent literature novelty retrieval, this project does not have the same products and technologies at home and abroad.
Facing more than 30 million hepatitis B patients in China, "anti-HBV human monoclonal antibody targeted preparation" has the advantages of good curative effect and low price. From the clinical curative effect, the clinical cure rate of "anti-HBV human monoclonal antibody targeted preparation" is 75.6%, and the effective rate is 9 1. 1%, which greatly exceeds the curative effect of other hepatitis B drugs at present. Moreover, compared with interferon-α, the interferon dose of this product is only one third of the former, and the curative effect is 189% of interferon. Clinical research shows that 25% of patients who use interferon have rebound (relapse) after cure, but this product has no such situation after clinical treatment.
In terms of price, patients who use interferon need about 654.38+0.5 million yuan for a course of treatment, but this product can reduce the cost by less than 50% because of its small dose, and even by 70% to 75% after mass production. Therefore, this product is a drug with high curative effect and low price, which is of great significance to patients.